Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to firstname.lastname@example.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 16 September 2016 | By Zachary Brennan
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on Friday recommended that medicines manufactured by Maryland-based contract manufacturing organization (CMO) Pharmaceutics International (Pii) should no longer be available in the EU, except for Ammonaps (sodium phenylbutyrate), which is used to treat a rare disease and is considered critical for public health.
The recommendation follows a good manufacturing practice (GMP) review after a follow-up inspection of the site by the UK’s Medicines and Health products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA).
MHRA disclosed the critical deficiencies at two of Pii’s Maryland facilities in June.
In the reports, outlined in two separate statements of non-compliance published to the EurdraGMP database, the inspectors say they identified a "failure of organizational and technical measures to minimize the risk of cross-contamination between hazardous and non-hazardous products manufactured in the same manufacturing facilities using shared equipment [and a] failure of the quality unit to ensure the effective operation of the quality system," at both sites during inspections that ended in February.
Regarding the failure of the sites' quality systems, the inspectors said the sites displayed a "gross failure of change management," by using an "unqualified" high-performance liquid chromatography system, and an employing an "unacceptable approach to production equipment qualification."
CHMP also says the inspection found that corrective measures previously agreed to had not been appropriately implemented.
“Although there is no evidence of a defect in any of the medicines produced at the site or of harm to patients, EMA’s Committee for Medicinal Products for Human Use (CHMP) concluded, as a precaution, that supply of non-critical medicines should be stopped. In addition, CHMP requested the site to implement corrective measures to ensure compliance with GMP standards,” a notice published Friday says.
CHMP’s recommendation will have an impact on the availability of medicines from Pii, including:
The European Commission will decide if the recommendation should be turned into a legally binding decision valid throughout the EU.
The deficiencies come as Pii announced earlier in September a definitive agreement with a consortium of investors, led by Signet Healthcare Partners and including Athyrium Capital Management, Hildred Capital Partners and Pharmascience Inc., an investment of $93 million in exchange for an equity stake in the company and debt refinancing.
EMA: Pharmaceutics International Inc., US: supply of non-critical medicines to EU to be stopped due to manufacturing failings
Tags: Pharmaceutics International, CHMP, US contract manufacturing of drugs
Regulatory Focus newsletters
All the biggest regulatory news and happenings.